Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-a Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study

Objective

To report maintenance of response in joint, skin, and composite efficacy outcomes to 1 year in bimekizumab (BKZ)-treated patients with psoriatic arthritis (PsA) and inadequate response or intolerance to TNF- α inhibitors (TNFi-IR) who were responders at Week 16 of the BE COMPLETE study.

Background

- PsA is a chronic disease affecting multiple domains; however, patients can experience loss of response with long-term therapy.¹ Maintaining long-term treatment responses in patients with prior TNFi-IR is of clinical interest.²
- BKZ, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, demonstrated rapid and clinically meaningful improvements in joint and skin efficacy outcomes that were sustained to Week 52.³⁻⁶

Methods

- BE COMPLETE (NCT03896581), a 16-week double-blind phase 3 study, included TNFi-IR patients with active PsA. Patients completing Week 16 were eligible to enter an open-label extension, BE VITAL (NCT04009499).
- Maintenance of response is reported as the percentage of BKZ-randomized Week 16 responders who met the response criteria at subsequent study visits for American College of Rheumatology (ACR)20/50/70, Psoriasis Area and Severity Index (PASI)75/90/100, minimal/very low disease activity (MDA/VLDA), Disease Activity Index for Psoriatic Arthritis (DAPSA) remission/low disease activity (REM+LDA; \leq 14) and remission (REM; \leq 4), and composite ACR50+PASI100 responses.
- Week 16 responders are reported using non-responder imputation (NRI). Week 52 maintenance data are reported as observed case (OC) and using NRI.
- Treatment-emergent adverse events (TEAEs) to Week 52 are reported for patients who received ≥ 1 dose of BKZ.

Results

- Overall, 263 (98.5%) patients completed Week 16. Of those patients initially randomized to BKZ, 236/267 (88.4%) completed Week 52.
- Baseline demographics and disease characteristics are reported in **Table 1**.
- At Week 16, 116 (43.4%; NRI) BKZ-treated patients achieved ACR50. Of those responders, 80.2% (NRI) and 86.1% (OC) maintained ACR50 response at Week 52 (Figure 1). Similar results were seen across other ACR endpoints: ACR20/70 was achieved by 179 (67.0%) and 71 (26.6%) patients, respectively, at Week 16 (NRI). At Week 52, ACR20/70 was maintained by 81.6%/83.1% (NRI) and 89.6%/85.5% (OC) of patients.
- Of 176 patients with psoriasis affecting \geq 3% body surface area (BSA) at baseline, 121 (68.8%) and 103 (58.5%) achieved PASI90/100 at Week 16. Robust maintenance of response was observed in high proportions (>84%) of these patients to Week 52 (Figure 2). 145 (82.4%) achieved PASI75; 88.3% maintained response to Week 52.
- A high proportion of Week 16 responders for MDA, DAPSA REM+LDA, and ACR50+PASI100 maintained their responses at Week 52 (Figures 3–5).
- Response was maintained to Week 52 for 66.7% (NRI) and 68.6% (OC) of patients that achieved VLDA at Week 16. 66.7% (NRI) of the 24 (9.0%) patients that achieved DAPSA REM at Week 16 maintained response to Week 52.
- To Week 52, 243/388 (62.6%) BKZ-treated patients reported >1 TEAE and 23 (5.9%) reported serious TEAEs.

Conclusions

Across all joint, skin, and composite outcomes assessed, bimekizumab demonstrated robust maintenance of response at Week 52 in TNFi-IR patients with PsA who responded to treatment at Week 16. The safety profile was consistent with previous reports.^{2,3}

Summary





٦	Га	b	le	1


	Ľ.	
		_
		f
		I

	BKZ 160 mg Q4W n=267	
Age, years, mean (SD)	50.1 (12.4)	
Male , n (%)	130 (48.7)	
BMI, kg/m ² , mean (SD)	30.1 (6.5)	
Time since first PsA diagnosis, ^a years, mean (SD)	9.6 (9.9)	
Concomitant methotrexate, n (%)	119 (44.6)	
BSA affected by psoriasis ≥3%, n (%)	176 (65.9)	
PASI score , ^b mean (SD)	10.1 (9.1)	
TJC (of 68 joints) , mean (SD)	18.4 (13.6)	
SJC (of 66 joints), mean (SD)	9.7 (7.5)	
Enthesitis (LEI >0), n (%)	106 (39.7)	
Score, ^c mean (SD)	2.6 (1.5)	
Dactylitis (LDI >0) , n (%)	34 (12.7)	
Score, ^d mean (SD)	72.7 (114.4)	
hs-CRP ≥6 mg/L , n (%)	118 (44.2)	
HAQ-DI, mean (SD)	0.97 (0.59)	
PtAAP, ^e mean (SD)	58.3 (24.2)	

Sec subject is locy and sec a PsA: psoriatic arthritis; PtAAP: Patient's Assessment of Arthritis Pain; Q4W: every 4 weeks; REM: remission; SD: standard deviation; SJC: swollen joint count; TRFi-IR: inadequate response/intolerance to tumor necrosis factor-α inhibitors; VAS: visual analog scale; VLDA: very low disease activity.

Innovation, University of Bath, Bath, UK; ³Department of Internal Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA; ⁴Division of Rheumatology, ASST Gaetano Pini-CTO, Salt Lake City, UT, USA; ¹⁰UCB Pharma, Slough, UK; ¹¹UCB Pharma, Slough, UK; ¹¹UCB Pharma, Slough, UK; ¹¹UCB Pharma, Slough, UK; ¹²Allergy, Immunology & Rheumatology, Salt Lake City, UT, USA; ¹⁰UCB Pharma, Slough, UK; ¹¹UCB Pharma, Slough, UK; ¹¹UCB, Sl ti Eisai, Eli Lilly, GSK, Janssen, AbbVie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria, Pharma; YT: Speaking fees, and/or honoraria from AbbVie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, GSK, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, GSK, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Biogen, BMS, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, GSK, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, GSK, Janssen, LEO Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; YT: Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gilead, Regeneron, Sanofi, Sun Pharma; Speaking fees, and/or honoraria from AbbVie, Amgen, Eli Lilly, Gi Bureau for AbbVie. Celgene. Janssen. Merck. Novartis. Pfizer. and UCB Pharma: Disea. Merck. Novartis. Pfizer. and UCB Pharma: Disea. Merck. Novartis. Pfizer. and UCB Pharma: Disea. Merck. Novartis. Pfizer. and UCB Pharma: Speaker's bureau for AbbVie. Celgene. Janssen. Merck. Novartis. Pfizer. and UCB Pharma: Disea. Merck End UCB Pharma; Bi: Employees and shareholders, End UCB Pharma; Bi: Employees and shareholders, End UCB Pharma; Bi: Employees and shareholders, Pharma; Bi: Employees and shareholders, Pharma; Bi: Employees and UCB Pharma; Consultant for AbbVie, Consultant for AbbVie, Consultant for AbbVie, Consultant for AbbVie, Amgen, Eli Lilly, Galapagos, Galderma; Bi: Employees and shareholders, Pharma; Bi: Employees and Shareholders, Pharma; Bi: Employees and Shareholders, Pharma; Consultant for AbbVie, End UCB Pharma; Bi: Employees and Shareholders, Pharma; Bi: Employees, End UCB Pharma; Bi: Employees and Shareholders, Pharma; Bi: Employees and Shareholders, Pharma; Bi: Employees,






A high proportion of TNFi-IR patients who responded to BKZ treatment at Week 16 maintained their response to Week 52 across multiple domains

[a] Values shown here are NRI; [b] In patients with psoriasis affecting at least 3% BSA at baseline.

Baseline patient demographics and disease characteristics for TNFi-IR patients



[d] In patients with dactylitis at baseline (LDI >0); [e] PtAAP VAS 0 (no symptoms) to 100 (severe symptoms)

2252

William R. Tillett,^{1,2} Joseph F. Merola,^{3,4} Yoshiya Tanaka,⁵ Ennio G. Favalli,⁶ Dennis McGonagle,⁷ Diamant Thaçi,⁸ Jessica A. Walsh,⁹ Barbara Ink,¹⁰ Rajan Bajracharya,¹⁰ Jason Coarse,¹¹ Christopher T. Ritchlin¹²

this poster, scan the QR code or visit: UCBposters.com/ACR2



Poster ID: 225 Link expiration November 29, 20